A liquid biopsy in primary lung cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Genetics

Background:

• Tissue biopsy is the gold standard for molecular profiling in primary lung cancer treatment decisions.
• Tumor biopsies present limitations such as invasiveness and accessibility challenges.
• Liquid biopsies offer potential advantages over traditional tissue biopsies.

Purpose of the Study:

• To describe blood-based liquid biopsies.
• To review the current status of plasma genotyping in primary lung cancer.
• To discuss future perspectives of plasma genotyping in lung cancer.

Main Methods:

• Review of current literature on liquid biopsies and plasma genotyping.
• Focus on cell-free DNA analysis in plasma for molecular profiling.
• Detection of epidermal growth factor receptor (EGFR) gene mutations.

Main Results:

• Plasma genotyping for EGFR mutations is approved and clinically applicable.
• Liquid biopsies are emerging as a viable alternative to tissue biopsies.
• Advances in molecular technologies facilitate clinical integration of liquid biopsies.

Conclusions:

• Blood-based liquid biopsies are valuable tools for molecular profiling in primary lung cancer.
• Plasma genotyping aids in selecting patients for EGFR tyrosine kinase inhibitor therapy.
• Liquid biopsies represent a significant advancement in the clinical management of lung cancer.